Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm

blonca9
Jul 19, 2023
1 min read

Al Collinson of TheracosBio discusses his plan to sell the SGLT2 inhibitor Brenzavvy for a deeply discounted price compared to larger competitors on the market.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight